Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation and Depletion (2016 - 2018)

Cytokinetics (CYTK) has disclosed Depreciation and Depletion for 3 consecutive years, with -$359000.0 as the latest value for Q4 2018.

  • Quarterly Depreciation and Depletion fell 160.85% to -$359000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2018, down 36.84% year-over-year, with the annual reading at $10.1 million for FY2025, 6.32% up from the prior year.
  • Depreciation and Depletion for Q4 2018 was -$359000.0 at Cytokinetics, down from $268000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $673000.0 in Q1 2018, with the low at -$359000.0 in Q4 2018.
  • Average Depreciation and Depletion over 3 years is $364777.8, with a median of $439000.0 recorded in 2017.
  • The sharpest move saw Depreciation and Depletion surged 222.4% in 2017, then crashed 160.85% in 2018.
  • Over 3 years, Depreciation and Depletion stood at $183000.0 in 2016, then soared by 222.4% to $590000.0 in 2017, then plummeted by 160.85% to -$359000.0 in 2018.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at -$359000.0, $268000.0, and $618000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.